Partnering

VIA is looking to expand its portfolio of products and development projects through in-licensing, acquisition and co-development collaborations. We are open to partnering with companies on the development of our products that provide therapeutic benefits to patients in the areas of cardiovascular and metabolic diseases.

With a pipeline of preclinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in key pathways in cardiovascular and metabolic disease, the VIA team provides our partners with accomplished leadership and development expertise capabilities. By focusing on key therapeutic areas, VIA is able to offer a unique collaborative approach for its partners to both develop and commercialize novel, high-value therapeutics that solve unmet medical needs.

If you are interested in discussing potential partnering opportunities with the VIA team, please contact us directly:

Larry Cohen, PhD
President & CEO
Tel: 415.283.2209
E-mail: larry.cohen@viapharmaceuticals.com

Click here for more informating regarding our lead candidate, VIA-2291

via 2291 broad development plan